Abstract Library

#4304 Co-targeting the Endocannabinoid System (ES) and mTOR in NEN potentiates their anti-tumour effect via unique metabolic changes

Introduction: The current treatment of neuroendocrine neoplasms (NEN) has limited efficacy, highlighting the need for novel therapeutic approaches. We have previously shown the potential therapeutic benefit when combining ES blocking with Everolimus (Eve).

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Kogot-Levin A, Abramovich I, Agranovich B, Polak D,

Keywords: Neuroendocrine neoplasm, Endocannabinoid system, Everolimus, metabolic Changes, metabolomics,

#4163 Metabolite biomarker discovery for pancreatic neuroendocrine tumors using metabolomic approach

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the tumors’ aberrant changes. However, the metabolic plasticity of pancreatic neuroendocrine tumors (pNET) is still unknown. pNETs are heterogeneous which makes their diagnosis, prognosis and therapeutic management difficult.

Conference:

Presenting Author:

Authors: Jannin A, Dessein A, Dabo S, Descat A, Vantyghem M,

Keywords: pancreatic NET, diagnostic biomarker, plasma metabolites, molecular pathways,

#4086 Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the aberrant changes that support cancer cells proliferation and survival. In a previous metabolomics study carried out by our group, multiplatform untargeted metabolomic profiling (GC-MS, CE-MS and LC-MS) performed on plasma samples from 77 advanced G1-2 extra-pancreatic NET patients demonstrated that these patients have a distinct metabolomic profile, and identified methionine, porphyrin and tryptophan metabolism as the most relevant dysregulated pathways associated with the prognosis of NETs. Furthermore, a 3-metabolite signature was able to stratify patients in 3 distinct prognostic clusters, with cluster 3 associated with the best prognosis.

Conference:

Presenting Author:

Authors: La Salvia A, Lens-Pardo A, Carretero-Puche C, Capdevila J, Benavent M,

Keywords: metabolimics, prognostic biomarker, lung neuroendocrine tumor, metabolomic signature,

#3997 FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression

Introduction: More than 60% of pancreatic neuroendocrine neoplasms (PanNENs) represent metastases when diagnosed. Metabolic alterations have been recognized as one of the hallmarks of tumor metastasis. However, little is known about the molecular mechanism of metabolic changes regulating PanNEN progression.

Conference:

Presenting Author:

Authors: Hu C,

Keywords: metabolic alteration, tumor progression, pancreatic neuroendocrine neoplasm, FOXA2, INHBA, epithelial-mesenchymal transition,

#3765 Heterogeneity and potential therapeutic targets of rectal neuroendocrine tumors by single cell RNA-sequencing combined with spatial omics

Introduction: The incidence of rectal neuroendocrine tumors (rNETs) has increased rapidly in the past 30 years. However, the molecular mechanism of its occurrence and development is still unclear, and the basic research is relatively backward.

Conference:

Presenting Author:

Authors: Bai J, Tang Q,

Keywords: neuroendocrine tumor, single cell RNA sequencing, spatial transcriptome, heterogeneity, tumor microenvironment, phospholipase d3, metastasis,